Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366594 | 0.84 | GPR84 (0.33) | — | |
| SCHEMBL3365441 | 0.84 | KDM1A (0.35) | KDM1AKDM1B | |
| SCHEMBL30076924 | 0.83 | TDP1 (0.33) | CA2HDAC1HDAC8 | |
| SCHEMBL29387214 | 0.81 | KDM1A (0.32) | USP28KDM1AKCNH2KDM1B | |
| SCHEMBL707949 | 0.81 | KDM1A (0.32) | USP28KDM1AKCNH2KDM1B | |
| SCHEMBL1239117 | 0.78 | HDAC1 (0.40) | CA2USP28HDAC1HDAC8 | |
| SCHEMBL30517174 | 0.78 | HDAC1 (0.40) | CA2USP28HDAC1HDAC8 | |
| SCHEMBL31394862 | 0.77 | KDM1A (0.32) | CA2KDM1AKCNH2KDM1BCYP1A2 | |
| SCHEMBL17006055 | 0.76 | RAD52 (0.44) | CA2NPSR1 | |
| SCHEMBL31152 | 0.76 | GRIA1 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324235-B2 | Heterocyclic spiro-compounds | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| EP-2134720-B1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2134720-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | Novartis Ag (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008119744-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | REN, NR3C2, CYP21A2 | CA2 1558/4885USP28 4748/4885KDM1A 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.